FINDER 2 2010

NCT00313170

A randomised clinical trial investigating the effect of fulvestrant 500mg versus fulvestrant 250mg in Western postmenopausal women recurring or progressing after prior endocrine therapy

1 Treatments

<table>
<thead>
<tr>
<th>Studied treatment</th>
<th>500 mg (high dose [HD]; 500 mg/month plus 500 mg on day 14 of Month 1).</th>
</tr>
</thead>
</table>

[2] Opt

<table>
<thead>
<tr>
<th>Control treatment</th>
<th>fulvestrant: 250 mg/month (approved dose [AD]);</th>
</tr>
</thead>
<tbody>
<tr>
<td>Concomittant treatment</td>
<td>-</td>
</tr>
</tbody>
</table>

2 Patients

<table>
<thead>
<tr>
<th>Patients</th>
<th>Western postmenopausal women recurring or progressing after prior endocrine therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion criteria</td>
<td>-</td>
</tr>
</tbody>
</table>

3 Methods

| Blinding | - |
| Design | - |
| Centers | - |
| Geographical area | - |
| Sample size | -18 (-9 / -9) |
| ArretTrt1 | - |
| ArretTrt0 | - |
| PeriodeInclusion | - |
| Hypothese | - |
4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>RR</td>
<td>-/-9</td>
<td>-/-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>time to progression (TTP)</td>
<td>-/-9</td>
<td>-/-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>PFS</td>
<td>-/-9</td>
<td>-/-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>OS</td>
<td>-/-9</td>
<td>-/-9</td>
<td>NA</td>
<td>-</td>
</tr>
</tbody>
</table>

5 References


6 Comments